There is no evidence that starting
antiretroviral therapy leads HIV-positive injecting drug users to have more
risky sex, Canadian researchers report in the online edition of AIDS. There was no increase in reported
sexual activity, unprotected sex, or number of partners.
“Concerns regarding the expansion of access
to ART [antiretroviral therapy] for IDU [injecting drug user] populations due to
fears of increased HIV risk behaviour in the period following ART initiation
are unsupported,” comment the investigators.
Treatment with combination antiretroviral
therapy can significantly increase the prognosis of HIV-positive individuals.
Such treatment can also dramatically reduce the risk of transmission of the
virus to HIV-negative individuals.
HIV treatment can work well in injecting
drug users. However, some doctors are reluctant to initiate treatment in drug
users. This is because of a fear that this group of patients may not adhere to
their treatment.
Moreover, some research has pointed to
increased levels of sexual risk taking amongst individuals after they start HIV
treatment.
Therefore investigators from AIDS Care
Cohort to Evaluate Exposure to Survival Services (ACCESS) in Vancouver, British
Columbia, undertook a prospective study that involved 457 HIV-positive
injecting drug users. All completed a baseline interview about their sexual
behaviour in the previous six months. A total of 197 of these people
started HIV therapy, and then completed another interview about their sexual activity six
to twelve months after initiating such treatment. The period of the study was between 1996 and 2007.
At baseline, 72% of patients reported that
they had had sexual intercourse in the preceding six months. Recent unprotected
anal or vaginal intercourse was reported by 35% of individuals, and the median
number of reported sex partners was one.
There was no evidence that starting HIV
treatment increased sexual activity. Just over a quarter (51) of the patients who
had initiated antiretroviral therapy reported any sexual behaviour in the
preceding six months.
Moreover, starting treatment with anti-HIV
drugs did not increase the risk of engaging in unprotected sex. Anal or vaginal
sex without a condom was reported by 17% of patients in the six to twelve
months after the initiation of antiretroviral therapy.
Nor did the initiation of HIV treatment
increase the risk of having multiple sex partners. Just over a quarter of
individuals taking antiretroviral therapy reported having two or more sex
partners in the six to twelve month period after they started this treatment.
The investigators then performed a series
of sensitivity analyses. They found no evidence that a higher CD4 cell count
after starting treatment was associated with either unprotected sex or a
greater number of sex partners.
Nor did sexual risk behaviour increase in
the longer term. There was no increase in overall sexual activity in the two
years after HIV treatment was started, and the proportion of patients reporting
unprotected sex or multiple partners remained stable.
“ART initiation was not associated with
increases in sexual activity or risk behaviour. Given these findings, concerns
regarding potential increases in or resumption of sexual risk behaviour among
IDUs following the initiation of HIV therapy appear to be unfounded,” comment
the investigators.
However, the investigators did find other factors were associated with sexual risk taking in the period after
HIV treatment was started. Unprotected sex was associated with having a partner
(p < 0.001), sex work (p < 0.001),
and syringe sharing (p < 0.001). Having multiple partners was
associated with older age (p < 0.001), female sex (p < 0.001), crack or
heroin use (both p < 0.001), and syringe sharing (p < 0.001).
The investigators “recommend the immediate
implementation and evaluation of novel programmes to reduce barriers to HIV
care and increase uptake of ART among IDUs”.